GeneIII produces L-ergothioneine through whole-cell fermentation, followed by purification and ingredient testing. Finished capsules undergo separate testing for L-ergothioneine content and specified quality parameters.
From fermentation to the GeneIII Original L-Ergothioneine 30 mg capsule, this guide explains the purpose of each production stage, the quality checks involved, and the supporting records—from ingredient specifications to finished-product test results.
Key Takeaways
- GeneIII uses whole-cell fermentation followed by separation and purification to produce its L-ergothioneine ingredient.
- Quality assessment covers more than purity: it includes ingredient characteristics, residual substances, capsule content and microbiological testing.
- Ingredient specifications and individual test results serve different purposes. GeneIII’s documentation identifies the material, method and production stage associated with each.
From Fermentation to L-Ergothioneine Powder
The FDA response to GRN 001270 summarizes the manufacturing process described in GeneIII’s notification. The following sequence is an editorial summary of that description:
Fermentation → Heat treatment → Filtration and membrane separation → Cation-exchange chromatography → Concentration and decolorization → Crystallization → Centrifugation → Drying and sieving
This describes the notified ingredient’s production route; It is not a separate FDA manufacturing certification.
Read the manufacturing description on page 3 of the FDA response
1. Whole-Cell Fermentation
Fermentation is the production stage. GeneIII uses a biological system to produce L-ergothioneine, rather than extracting the finished ingredient from mushrooms.
The distinction between production and purification matters. Creating the target compound is the starting point; obtaining an ingredient suitable for formulation also requires separating it from the surrounding production mixture.
Whole-cell fermentation therefore works together with downstream processing. The production route alone is not the finished quality assessment.
2. Separation and Purification
Following fermentation, the material passes through a sequence of separation operations.
Filtration and membrane processes help separate components of the production mixture. Chromatography provides an additional separation mechanism, while concentration and decolorization prepare the material for recovery.
Using several operations allows purification to address different properties of the mixture. This is why a manufacturing description includes more than a single statement that an ingredient has been “filtered” or “purified.”
3. Recovery of the Finished Ingredient
Crystallization recovers the ingredient in solid form. Subsequent separation, drying and sieving prepare the powder for further assessment and use in formulation.
At this point, manufacturing and analytical testing meet: the recovered material can be examined against defined specifications. A production method describes the route taken; test results establish the measured characteristics of a particular sample.
Quality Control From Ingredient to Capsule
GeneIII’s quality records cover ingredient specifications, production-batch testing and finished-capsule analysis. The table below explains what each record addresses, the results or specifications it contains, and where to find further information.
| Quality-Control Area | What Is Assessed | Specification or Reported Result | Scope of the Record | Supporting Record and Access |
|---|---|---|---|---|
| Ingredient specification | Ergothioneine content, loss on drying, residual ethanol and heavy metals | Ergothioneine ≥99.5%; loss on drying ≤0.5%; ethanol ≤500 mg/kg; lead, arsenic, cadmium and mercury each <0.1 mg/kg | Ingredient specifications described in GeneIII’s GRAS notification; distinct from finished-capsule test results | FDA response to GRN 001270 |
| Production-batch consistency | Separate production batches assessed against the ingredient specifications | Analytical data from five nonconsecutive batches meeting the stated specifications | The five batches described in the submission | FDA response to GRN 001270 |
| Ingredient chromatographic purity | HPLC peak-area normalization | >99.99% for the submitted ingredient sample | Sample-specific chromatographic purity; interpreted according to the report’s method | WEIPU SHA01-23110824-FX-01R2 — Request report details |
| Ingredient characterization | Specific rotation and specified physicochemical, metal and residual-solvent measurements | Individual results and methods are listed in the report | The submitted ingredient sample and the tests performed | SGS ASH24-0085048-01 — Request report details |
| Finished-capsule content | L-ergothioneine content per capsule | 31.94 mg per capsule in the tested sample | Submitted capsules identified as batch P776796; the GeneIII Original product label declares 30 mg per capsule | SGS ASH25-0079758-03 — Request report details |
| Finished-capsule quality and safety | Specified microbiological, metal and physicochemical parameters | Tested items met the stated limits recorded in the report | Submitted capsules identified as batch P777151 and the parameters covered by that report | SGS ASH26-0018042-02 — Request report details |
For more detailed documentation, contact GeneIII with the product name and lot number shown on your packaging. The team can advise which supporting records are available and how they relate to your product. The report-request links above lead to GeneIII’s contact page, rather than directly to downloadable laboratory reports.
Ingredient Specifications and Batch Consistency
A specification defines the characteristics against which a material is assessed. A batch result records what was measured in a particular sample.
This distinction is central to consistent manufacturing. Repeated production requires an established reference, rather than relying only on the best result obtained from an individual sample.
GeneIII submitted analytical results from five nonconsecutive production batches as part of GRN 001270. The FDA response, page 3, records that these batches met the stated ingredient specifications. This provides batch-level information alongside the manufacturing description and individual laboratory reports, helping explain how ingredient consistency is assessed.
Understanding the Two Purity Figures
GeneIII’s quality documentation includes an ingredient specification and a laboratory result that describe different aspects of purity:
- ≥99.5% ergothioneine content: The ingredient specification described in the FDA response to GeneIII’s GRAS notification, GRN 001270.
- >99.99% chromatographic purity: The result reported by WEIPU for a submitted GeneIII ingredient sample, measured using HPLC peak-area normalization.
The ingredient specification defines the stated content requirement. The WEIPU result describes the proportion of the target peak within the chromatographic peaks included in the analysis. Each figure should therefore be interpreted according to its method and scope, rather than treated as a direct comparison.
Together with separate testing for residual solvents, metals and microbiological quality, these records help explain how GeneIII evaluates ingredient quality. Finished-capsule testing provides additional information about capsule content and the quality parameters assessed after formulation.
The ingredient specification can be reviewed in the FDA response to GRN 001270. For further details about the WEIPU report and available supporting documentation, contact GeneIII.
Why Finished Capsules Are Tested Separately
Ingredient testing and finished-product testing take place at different stages.
The ingredient report describes the material before formulation. Finished-capsule testing examines the product after formulation and encapsulation. This provides information directly relevant to the form supplied to consumers.
Capsule Content
Content testing measures the amount of L-ergothioneine in the tested capsules. It addresses a different question from ingredient purity: how much of the ingredient is present per capsule?
GeneIII’s finished-product content record is included in the quality-control table above. Its measured value and the label declaration are shown separately so that the laboratory result is not mistaken for a different serving recommendation.
For everyday use, the label remains the reference for the declared amount and directions.
Microbiological and Chemical Quality
Finished-product safety testing examines specified quality parameters rather than relying on the ingredient’s purity result.
The capsule report identified in the table includes microbiological and metal testing. These categories address different aspects of quality:
| Testing Category | Its Role in Finished-Product Assessment |
|---|---|
| Microbial counts | Measures specified groups of microorganisms under the test conditions |
| Specified pathogens | Checks for the named organisms using the reported method |
| Metals | Measures the listed elements against the applicable report limits |
| Other physical or chemical parameters | Adds information about the characteristics assessed in that sample |
A result such as “not detected” is interpreted according to the report’s method and reporting limit. It does not mean that a test establishes the absolute absence of a substance.
Together, content and safety testing provide a broader assessment than either would alone.
Manufacturing Practices and Regulatory Documentation
The current GeneIII Original L-Ergothioneine product page states that the capsules are manufactured in a cGMP-compliant facility. This concerns manufacturing practices and is separate from the sample-specific testing performed by independent laboratories.
For information about the relevant manufacturing facility and available supporting documentation, contact GeneIII.
These forms of documentation are complementary. A laboratory result does not itself certify a facility, while a manufacturing-system statement does not replace product testing.
GeneIII’s GRAS notification, GRN 001270, received an FDA “no questions” response concerning the ingredient’s specified intended food uses. This is not FDA approval of the finished supplement or its health benefits.
Read the FDA response to GRN 001270
What This Means for Product Quality
GeneIII’s manufacturing approach connects three practical elements:
- A defined production route: how L-ergothioneine is produced and purified.
- Ingredient assessment: how the material’s composition and other characteristics are evaluated.
- Finished-product testing: how capsule content and specified safety parameters are checked.
This approach makes quality information more specific. Instead of relying on a single purity percentage, the documentation addresses the production process, the tested ingredient and the finished capsule.
For product details, serving directions and storage information, refer to the current label.
View GeneIII L-Ergothioneine product details
Frequently Asked Questions
Q1: Is GeneIII L-Ergothioneine Extracted From Mushrooms?
GeneIII produces its L-ergothioneine through whole-cell fermentation. Mushrooms are a natural dietary source of ergothioneine, but they are not the extraction source for this production route.
Q2: Why Does Manufacturing Require Several Purification Steps?
Different separation operations address different properties of the production mixture. Combining them allows the target ingredient to be recovered and prepared for testing. The resulting material is then assessed using the relevant specifications and analytical methods.
Q3: Does a High Purity Result Cover All Aspects of Product Quality?
Purity is one part of quality assessment. Capsule content, microbiological measurements, specified metals and other tested characteristics provide additional information. They are evaluated through their own methods rather than inferred from the purity percentage.
Q4: Why Test the Finished Capsule if the Ingredient Has Already Been Tested?
The two samples represent different production stages. Ingredient testing characterizes the starting material; finished-capsule testing examines the formulated product, including its L-ergothioneine content per capsule and specified safety parameters.
Q5: How Can I Request Quality Documentation?
Contact GeneIII with the product name and batch or lot number shown on the packaging to request the applicable quality documentation. The identifier helps distinguish the relevant product batch from other samples or reports.
Sources and Further Reading
- FDA Response to GeneIII GRAS Notification GRN 001270 — Page 3 summarizes the manufacturing process, ingredient specifications and production-batch information submitted by GeneIII.
- How to Read an Ergothioneine Test Report: Purity, Content and Safety — A practical guide to sample identifiers, test methods, reported results and document verification.
- How to Verify L-Ergothioneine Purity and Safety — Further guidance on ingredient purity, capsule content and safety testing.
Disclaimer
This content is for informational purposes only and does not constitute medical advice. If you are pregnant, breastfeeding, planning pregnancy, taking medication, or managing a medical condition, consult a qualified healthcare professional before use.
